Q1 Earnings Forecast for BioNTech Issued By Leerink Partnrs

BioNTech SE (NASDAQ:BNTX - Free Report) - Leerink Partnrs issued their Q1 2025 EPS estimates for shares of BioNTech in a report released on Monday, April 21st. Leerink Partnrs analyst D. Graybosch expects that the company will post earnings of ($5.78) per share for the quarter. The consensus estimate for BioNTech's current full-year earnings is ($3.88) per share. Leerink Partnrs also issued estimates for BioNTech's Q2 2025 earnings at ($2.70) EPS, Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at $0.07 EPS, FY2025 earnings at ($9.20) EPS, FY2026 earnings at ($3.87) EPS, FY2027 earnings at ($2.62) EPS, FY2028 earnings at ($1.79) EPS and FY2029 earnings at ($0.63) EPS.

BNTX has been the subject of a number of other research reports. HC Wainwright decreased their target price on shares of BioNTech from $150.00 to $145.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Truist Financial assumed coverage on shares of BioNTech in a report on Friday, January 10th. They issued a "buy" rating and a $172.00 price objective for the company. Canaccord Genuity Group reissued a "buy" rating and set a $171.44 target price on shares of BioNTech in a report on Tuesday, March 11th. Morgan Stanley decreased their price target on BioNTech from $145.00 to $139.00 and set an "overweight" rating for the company in a research note on Tuesday, March 11th. Finally, Citigroup began coverage on BioNTech in a research note on Thursday, March 13th. They issued a "buy" rating and a $145.00 price objective on the stock. Three analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $143.44.

BioNTech Trading Up 2.8 %

NASDAQ:BNTX opened at $104.68 on Wednesday. The stock has a market cap of $25.12 billion, a price-to-earnings ratio of -49.85 and a beta of 1.07. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. BioNTech has a 1 year low of $76.53 and a 1 year high of $131.49. The business has a fifty day moving average of $102.22 and a 200-day moving average of $110.75.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.70. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business's revenue was down 19.5% on a year-over-year basis. During the same period in the previous year, the firm posted $1.90 earnings per share.

Hedge Funds Weigh In On BioNTech

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jones Financial Companies Lllp grew its holdings in shares of BioNTech by 110.3% during the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock valued at $53,000 after buying an additional 246 shares in the last quarter. Quintet Private Bank Europe S.A. grew its stake in BioNTech by 823.5% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock valued at $88,000 after acquiring an additional 700 shares in the last quarter. Allianz SE acquired a new position in shares of BioNTech in the 4th quarter valued at about $90,000. GAMMA Investing LLC lifted its position in shares of BioNTech by 48.2% in the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company's stock worth $105,000 after purchasing an additional 300 shares in the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. acquired a new stake in shares of BioNTech during the fourth quarter worth approximately $137,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.